메뉴 건너뛰기




Volumn 58, Issue 3, 2013, Pages 872-880

Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; VIRUS DNA;

EID: 84883257597     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26436     Document Type: Article
Times cited : (196)

References (29)
  • 1
    • 33646337650 scopus 로고    scopus 로고
    • Hepatocellular carcinoma and hepatitis B virus
    • Chan HL, Sung JJ. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis 2006;26:153-161.
    • (2006) Semin Liver Dis , vol.26 , pp. 153-161
    • Chan, H.L.1    Sung, J.J.2
  • 2
    • 13444309139 scopus 로고    scopus 로고
    • A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone
    • Chan HL, Leung NW, Hui AY, Wong VW, Liew CT, Chim AM, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 2005;142:240-250.
    • (2005) Ann Intern Med , vol.142 , pp. 240-250
    • Chan, H.L.1    Leung, N.W.2    Hui, A.Y.3    Wong, V.W.4    Liew, C.T.5    Chim, A.M.6
  • 3
    • 19944428132 scopus 로고    scopus 로고
    • Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial
    • Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365:123-129.
    • (2005) Lancet , vol.365 , pp. 123-129
    • Janssen, H.L.1    van Zonneveld, M.2    Senturk, H.3    Zeuzem, S.4    Akarca, U.S.5    Cakaloglu, Y.6
  • 4
    • 21244447705 scopus 로고    scopus 로고
    • Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
    • Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-2695.
    • (2005) N Engl J Med , vol.352 , pp. 2682-2695
    • Lau, G.K.1    Piratvisuth, T.2    Luo, K.X.3    Marcellin, P.4    Thongsawat, S.5    Cooksley, G.6
  • 5
    • 80055059164 scopus 로고    scopus 로고
    • Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C
    • Liaw YF, Jia JD, Chan HL, Han KH, Tanwandee T, Chuang WL, et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology 2011;54:1591-1599.
    • (2011) Hepatology , vol.54 , pp. 1591-1599
    • Liaw, Y.F.1    Jia, J.D.2    Chan, H.L.3    Han, K.H.4    Tanwandee, T.5    Chuang, W.L.6
  • 7
    • 48549107919 scopus 로고    scopus 로고
    • Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b
    • Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008;135:459-467.
    • (2008) Gastroenterology , vol.135 , pp. 459-467
    • Buster, E.H.1    Flink, H.J.2    Cakaloglu, Y.3    Simon, K.4    Trojan, J.5    Tabak, F.6
  • 8
    • 77952725714 scopus 로고    scopus 로고
    • Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B
    • Wong VW, Wong GL, Yan KK, Chim AM, Chan HY, Tse CH, et al. Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51:1945-1953.
    • (2010) Hepatology , vol.51 , pp. 1945-1953
    • Wong, V.W.1    Wong, G.L.2    Yan, K.K.3    Chim, A.M.4    Chan, H.Y.5    Tse, C.H.6
  • 9
    • 70649104668 scopus 로고    scopus 로고
    • Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa
    • Buster EH, Hansen BE, Lau GK, Piratvisuth T, Zeuzem S, Steyerberg EW, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009;137:2002-2009.
    • (2009) Gastroenterology , vol.137 , pp. 2002-2009
    • Buster, E.H.1    Hansen, B.E.2    Lau, G.K.3    Piratvisuth, T.4    Zeuzem, S.5    Steyerberg, E.W.6
  • 10
    • 84863517149 scopus 로고    scopus 로고
    • Presence of precore and core promoter mutants limits the probability of response to peginterferon in HBeAg-positive chronic hepatitis B
    • Sonneveld MJ, Rijckborst V, Zeuzem S, Heathcote EJ, Simon K, Senturk H, et al. Presence of precore and core promoter mutants limits the probability of response to peginterferon in HBeAg-positive chronic hepatitis B. Hepatology 2012;56:67-75.
    • (2012) Hepatology , vol.56 , pp. 67-75
    • Sonneveld, M.J.1    Rijckborst, V.2    Zeuzem, S.3    Heathcote, E.J.4    Simon, K.5    Senturk, H.6
  • 11
    • 84857636648 scopus 로고    scopus 로고
    • Polymorphisms near IL28B and serological response to peginterferon in HBeAg-positive patients with chronic hepatitis B
    • Sonneveld MJ, Wong VW, Woltman AM, Wong GL, Cakaloglu Y, Zeuzem S, et al. Polymorphisms near IL28B and serological response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology 2012;142:513-520.
    • (2012) Gastroenterology , vol.142 , pp. 513-520
    • Sonneveld, M.J.1    Wong, V.W.2    Woltman, A.M.3    Wong, G.L.4    Cakaloglu, Y.5    Zeuzem, S.6
  • 13
    • 84859567945 scopus 로고    scopus 로고
    • Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B?
    • Janssen HL, Sonneveld MJ, Brunetto MR. Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B? Gut 2012;61:641-645.
    • (2012) Gut , vol.61 , pp. 641-645
    • Janssen, H.L.1    Sonneveld, M.J.2    Brunetto, M.R.3
  • 14
    • 77957958049 scopus 로고    scopus 로고
    • Prediction of sustained response to peginterferon alfa-2b for Hepatitis B e Antigen-positive chronic hepatitis B using on-treatment Hepatitis B surface Antigen decline
    • Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL. Prediction of sustained response to peginterferon alfa-2b for Hepatitis B e Antigen-positive chronic hepatitis B using on-treatment Hepatitis B surface Antigen decline. Hepatology 2010;52:1251-1257.
    • (2010) Hepatology , vol.52 , pp. 1251-1257
    • Sonneveld, M.J.1    Rijckborst, V.2    Boucher, C.A.3    Hansen, B.E.4    Janssen, H.L.5
  • 15
    • 79952206073 scopus 로고    scopus 로고
    • Further analysis is required to identify an early stopping rule for peginterferon therapy that is valid for all hepatitis B e antigen-positive patients
    • Piratvisuth T, Marcellin P. Further analysis is required to identify an early stopping rule for peginterferon therapy that is valid for all hepatitis B e antigen-positive patients. Hepatology 2010;53:1054-1055.
    • (2010) Hepatology , vol.53 , pp. 1054-1055
    • Piratvisuth, T.1    Marcellin, P.2
  • 16
    • 84856203453 scopus 로고    scopus 로고
    • Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-á2b: relation to response and HBV genotype
    • Sonneveld MJ, Rijckborst V, Cakaloglu Y, Simon K, Heathcote EJ, Tabak F, et al. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-á2b: relation to response and HBV genotype. Antivir Ther 2012;17:9-17.
    • (2012) Antivir Ther , vol.17 , pp. 9-17
    • Sonneveld, M.J.1    Rijckborst, V.2    Cakaloglu, Y.3    Simon, K.4    Heathcote, E.J.5    Tabak, F.6
  • 17
    • 0344737590 scopus 로고    scopus 로고
    • Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay
    • Deguchi M, Yamashita N, Kagita M, Asari S, Iwatani Y, Tsuchida T, et al. Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J Virol Methods 2004;115:217-222.
    • (2004) J Virol Methods , vol.115 , pp. 217-222
    • Deguchi, M.1    Yamashita, N.2    Kagita, M.3    Asari, S.4    Iwatani, Y.5    Tsuchida, T.6
  • 18
    • 79959247715 scopus 로고    scopus 로고
    • A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B
    • Sonneveld MJ, Rijckborst V, Boucher CA, Zwang L, Beersma MF, Hansen BE, et al. A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B. J Clin Virol 2011;51:175-178.
    • (2011) J Clin Virol , vol.51 , pp. 175-178
    • Sonneveld, M.J.1    Rijckborst, V.2    Boucher, C.A.3    Zwang, L.4    Beersma, M.F.5    Hansen, B.E.6
  • 19
    • 84860320431 scopus 로고    scopus 로고
    • Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients
    • Epub ahead of print]
    • Piratvisuth T, Marcellin P, Popescu M, Kapprell HP, Rothe V, Lu ZM. Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients. Hepatol Int 2011 [Epub ahead of print].
    • (2011) Hepatol Int
    • Piratvisuth, T.1    Marcellin, P.2    Popescu, M.3    Kapprell, H.P.4    Rothe, V.5    Lu, Z.M.6
  • 20
    • 77955984417 scopus 로고    scopus 로고
    • Pros and cons of peginterferon versus nucleos(t)ide analogues for treatment of chronic hepatitis B
    • Sonneveld MJ, Janssen HL. Pros and cons of peginterferon versus nucleos(t)ide analogues for treatment of chronic hepatitis B. Curr Hepat Rep 2010;9:91-98.
    • (2010) Curr Hepat Rep , vol.9 , pp. 91-98
    • Sonneveld, M.J.1    Janssen, H.L.2
  • 21
    • 38049008387 scopus 로고    scopus 로고
    • Modelling of early viral kinetics and pegylated interferon-alpha2b pharmacokinetics in patients with HBeag-positive chronic hepatitis B
    • ter Borg MJ, Hansen BE, Herrmann E, Zeuzem S, Cakaloglu Y, Karayalcin S, et al. Modelling of early viral kinetics and pegylated interferon-alpha2b pharmacokinetics in patients with HBeag-positive chronic hepatitis B. Antivir Ther 2007;12:1285-1294.
    • (2007) Antivir Ther , vol.12 , pp. 1285-1294
    • ter Borg, M.J.1    Hansen, B.E.2    Herrmann, E.3    Zeuzem, S.4    Cakaloglu, Y.5    Karayalcin, S.6
  • 22
    • 33748951529 scopus 로고    scopus 로고
    • Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response
    • ter Borg MJ, van Zonneveld M, Zeuzem S, Senturk H, Akarca US, Simon C, et al. Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response. Hepatology 2006;44:721-727.
    • (2006) Hepatology , vol.44 , pp. 721-727
    • ter Borg, M.J.1    van Zonneveld, M.2    Zeuzem, S.3    Senturk, H.4    Akarca, U.S.5    Simon, C.6
  • 23
    • 77954412012 scopus 로고    scopus 로고
    • Prediction of the response to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment
    • Hansen B, Buster EH, Steyerberg EW, Lesaffre E, Janssen HL. Prediction of the response to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment. J Med Virol 2010;82:1135-1142.
    • (2010) J Med Virol , vol.82 , pp. 1135-1142
    • Hansen, B.1    Buster, E.H.2    Steyerberg, E.W.3    Lesaffre, E.4    Janssen, H.L.5
  • 24
    • 39549114267 scopus 로고    scopus 로고
    • HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B
    • Fried MW, Piratvisuth T, Lau GK, Marcellin P, Chow WC, Cooksley G, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008;47:428-434.
    • (2008) Hepatology , vol.47 , pp. 428-434
    • Fried, M.W.1    Piratvisuth, T.2    Lau, G.K.3    Marcellin, P.4    Chow, W.C.5    Cooksley, G.6
  • 25
    • 38349108753 scopus 로고    scopus 로고
    • Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years
    • Fattovich G, Olivari N, Pasino M, D'Onofrio M, Martone E, Donato F. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut 2008;57:84-90.
    • (2008) Gut , vol.57 , pp. 84-90
    • Fattovich, G.1    Olivari, N.2    Pasino, M.3    D'Onofrio, M.4    Martone, E.5    Donato, F.6
  • 26
    • 84862664371 scopus 로고    scopus 로고
    • EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
    • European Association for the Study of the Liver.
    • European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-185.
    • (2012) J Hepatol , vol.57 , pp. 167-185
  • 27
    • 70349240414 scopus 로고    scopus 로고
    • Chronic hepatitis B: update 2009
    • Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-662.
    • (2009) Hepatology , vol.50 , pp. 661-662
    • Lok, A.S.1    McMahon, B.J.2
  • 28
    • 33644858331 scopus 로고    scopus 로고
    • Predicting cirrhosis risk based on the level of circulating hepatitis B viral load
    • Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-686.
    • (2006) Gastroenterology , vol.130 , pp. 678-686
    • Iloeje, U.H.1    Yang, H.I.2    Su, J.3    Jen, C.L.4    You, S.L.5    Chen, C.J.6
  • 29
    • 29944436855 scopus 로고    scopus 로고
    • Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level
    • Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.
    • (2006) JAMA , vol.295 , pp. 65-73
    • Chen, C.J.1    Yang, H.I.2    Su, J.3    Jen, C.L.4    You, S.L.5    Lu, S.N.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.